Samsung Pharmaceutical Goes Beyond Drug Supply to 'Sharing Life'; Employees Join Blood Donation
Predicted impact: Low
Blood donation social campaign; no financial impact on the company.
SAM Chun Dang Pharm삼천당제약
000250 · KOSDAQ · ₩000250 · 삼천당제약
₩187,600▼ ₩1,300 (0.69%)End-of-day · Oct 27, 2026 · End-of-day prices.
Price · 1Y −16.99%
- Market cap
- ₩4.4T
- Enterprise value
- ₩4.4T
- P/E
- 247.5×
- P/B
- 14.6×
- Dividend yield
- 0.0%
- ROE
- 5.9%
- Net margin
- 6.8%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−84.8% from the high
₩120,000Today: ₩186,700 – ₩201,000₩1,233,000
Returns
- 1W−8.5%
- 1M+13.2%
- 3M+34.5%
- 6M−56.6%
- YTD−19.3%
- 1Y−17.0%
- Volume today
- 96,932
- 0.6× the 20-day average
- Traded today
- ₩19B
- Listed shares
- 23,457,472
- EPS (12 months)
- ₩758
- Earnings yield 0.4%
AI research · InitiationSAM Chun Dang Pharm: Thin Profits and Very High Multiples After a Sharp One-Month Share RiseThe filed numbers show a company with steadily growing revenue and a recent recovery to modest profitability, but earnings remain small relative to a market value of about ₩5.0T.Read the full report →
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 34 of 100 (50 is a normal day for this stock).
- MomentumFlat15.4% over the last month; the price is below its 20-day average.
- News impactLow3 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Leveraged ETF flows
Estimated leveraged-ETF rebalance on Oct 26: sell ₩2.9B at the close (7.4% of 20-day average trading value)
On its 20 biggest days of the last 60 (moves of 3%+), the estimated pressure averaged 17.2% of trading value and pointed the same way 18 of 20 times.
- 2× KODEX KOSDAQ150 Leverage −₩2.4B
- -1× KODEX KOSDAQ150 Futures Inverse −₩203M
- 2× TIGER KOSDAQ150 Leverage −₩180M
- 2× RISE KOSDAQ150 Futures Leverage −₩52M
- -1× TIGER KOSDAQ150 Futures Inverse −₩5.7M
Mostly via futures: index funds hedge with KOSPI 200 / KOSDAQ 150 futures, spread here over the index's largest members by market value.
Final after the close. An intraday "if the close were now" estimate needs real-time prices, which we don't have yet.
Estimate based on ETF size and daily moves; actual trades may differ.
ETFs holding this
All ETFs →Held by 11 funds.
- KODEX KOSDAQ1501.7%
- KODEX KOSDAQ150 Leverage2×1.7%
- TIGER KOSDAQ1501.7%
- RISE KOSDAQ1501.7%
- TIGER KOSDAQ150 Leverage2×1.7%
- ACE KOSDAQ 1501.7%
- KIWOOM KOSDAQ1501.7%
- SOL KOSDAQ1501.7%
Estimated from the funds' index or underlying stock.
Futures and options
All stock futures →Futures (2026-11): 187,700
Basis +0.05% · implied rate +1.2%
Open interest 17,952 contracts
Futures and options can lose more than you put in. Figures describe the market; they are not predictions or recommendations. Paper trading only.
SAM Chun Dang Pharm stock overview
SAM Chun Dang Pharm (삼천당제약, KRX: 000250) is listed on KOSDAQ, in the Biotech & Pharma sector. Samchundang Pharm produces and sells prescription-focused ethical pharmaceuticals, including antibiotics, cardiovascular, gastrointestinal, and eye drop products, having been established in 1943. Its shares closed at ₩187,600 on Oct 27, 2026, down 0.69% on the day, giving it a market value of ₩4.4T.
Key facts
- Market cap
- ₩4.4T
- Sector
- Biotech & Pharma
- Latest price change
- −0.69%
- As of
- Oct 27, 2026
- Main business
- Samchundang Pharm produces and sells prescription-focused ethical pharmaceuticals, including antibiotics, cardiovascular, gastrointestinal, and eye drop products, having been established in 1943.
Quick answers about SAM Chun Dang Pharm
- What does SAM Chun Dang Pharm do?
- Samchundang Pharm produces and sells prescription-focused ethical pharmaceuticals, including antibiotics, cardiovascular, gastrointestinal, and eye drop products, having been established in 1943. Its products are manufactured at its Hwaseong plant in Gyeonggi-do, South Korea. Its subsidiary Optus Pharma manufactures and sells ophthalmic drugs such as eye drops, and other subsidiaries operate in the United States and Japan.
- What is the market cap of SAM Chun Dang Pharm?
- The market capitalisation of SAM Chun Dang Pharm was ₩4.4T at the close on Oct 27, 2026.
- Who are the largest shareholders of SAM Chun Dang Pharm?
- According to the latest official filings, the largest reported holders are Yoon Dae-in (37.61%, as of Oct 20, 2026); Jeon In-seok (3.41%, as of Jul 24, 2025); National Pension Service (1.34%, as of Dec 31, 2025).
- When is the next earnings report from SAM Chun Dang Pharm?
- Korean companies rarely announce results dates in advance. Based on when SAM Chun Dang Pharm filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own SAM Chun Dang Pharm?
- Yes. The National Pension Service held 1.34% of SAM Chun Dang Pharm shares as of Dec 31, 2025.
Company profile
Samchundang Pharm produces and sells prescription-focused ethical pharmaceuticals, including antibiotics, cardiovascular, gastrointestinal, and eye drop products, having been established in 1943. Its products are manufactured at its Hwaseong plant in Gyeonggi-do, South Korea. Its subsidiary Optus Pharma manufactures and sells ophthalmic drugs such as eye drops, and other subsidiaries operate in the United States and Japan.
Written by AI from the company's latest annual report.
- Korean name
- 삼천당제약
- Sector
- Biotech & Pharma
- CEO
- 전인석
- Founded
- Dec 1943
- Listed
- Oct 2000
- Listed shares
- 23,457,472
- Fiscal year ends
- Month 12
- Website
- www.scd.co.kr
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SK Bioscience302440 · ₩2.5T₩31,750−0.78%
Recent news
Samyang Biopharma Runs 'Love Blood Donation' Campaign, Employees Donate Blood Certificates
Predicted impact: Low
Blood donation campaign; no financial relevance.
Samcheok Pharmaceutical Expands Distribution of Pet Oral Supplement 'Dental Bio'… Entering Animal Hospitals and Door-to-Door Sales
Predicted impact: Low· Actual: −9.2% vs sector, volume 0.7× normal (5 trading days)
Pet supplement distribution expansion; small revenue impact for a large pharma.
Recent filings
See all- 5%+ holding reportOct 20, 2026
- Amended: Half-year report (Jun 2026)Oct 8, 2026
- Amended: Quarterly report (Mar 2026)Oct 8, 2026
- Amended: Major management matter relevant to investorsOct 1, 2026
- 5%+ holding reportAug 14, 2026
Titles in Korean until English translations are added.
Also known as: SAM Chun Dang Pharm / 삼천당제약 / 000250 / KRX:000250
Source: KRX statistical information